 BASEL, Switzerland, May 21, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV today announced the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency has adopted a positive opinion recommending the approval of RYEQO relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The European Commission will review the CHMP recommendation, and a final decision on the Marketing Authorization Application is expected to be available in approximately two months. The decision will be applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. 